Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking strong CYP450 3A inhibitors or inducers, you may need to stop them 14 days before starting alectinib and during the first three weeks of treatment.
What data supports the effectiveness of the drug Alectinib for non-small cell lung cancer?
The ALUR study showed that Alectinib significantly improved progression-free survival (the time during and after treatment that a patient lives with the disease without it getting worse) and had a better response rate in the brain compared to chemotherapy in patients with advanced ALK-positive non-small cell lung cancer who had already been treated with crizotinib.12345
Is Alectinib safe for humans?
Alectinib is generally well tolerated but can cause serious side effects like skin toxicity and hyperbilirubinemia (high levels of bilirubin in the blood). It is considered safer than some other similar treatments, but patients should be monitored for adverse effects, especially if they have had prior treatments.16789
How is the drug Alectinib different from chemotherapy for non-small cell lung cancer?
Alectinib is a targeted therapy specifically designed to block the action of a protein called ALK, which is involved in the growth of cancer cells, making it different from traditional chemotherapy that attacks rapidly dividing cells in general. This targeted approach can lead to fewer side effects and is particularly effective for patients with ALK-positive non-small cell lung cancer.1011121314
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with ALK-positive Non-Small Cell Lung Cancer who've had surgery to remove the tumor and are eligible for chemotherapy. They must have good blood and kidney function, agree to use effective contraception, and be able to follow study procedures. Excluded are those with significant health issues that could affect the study, prior cancer treatments or organ transplants, pregnant or breastfeeding women, certain GI disorders affecting drug absorption, HIV/AIDS patients, and those unlikely to comply with protocol.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants in the experimental arm receive alectinib for 24 months, while the control arm receives platinum-based chemotherapy for 4 cycles
Follow-up
Participants are monitored for disease recurrence and survival until death, withdrawal of consent, or study closure
Survival Follow-up
Participants enter a survival follow-up phase until death, withdrawal of consent, or study closure
Treatment Details
Interventions
- Alectinib
Alectinib is already approved in United States, European Union for the following indications:
- Metastatic ALK-positive non-small cell lung cancer (NSCLC)
- Adjuvant treatment following tumor resection in patients with ALK-positive NSCLC
- Metastatic ALK-positive non-small cell lung cancer (NSCLC)
- Adjuvant treatment following tumor resection in patients with ALK-positive NSCLC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University